Braz André, de Paula Eduardo Camila Cazerta, Pierce Alexander, Grond Alexandra, Kutikov Artem, Nakab Lauren
From Private Practice, Rio de Janeiro, Brazil.
Allergan Aesthetics, an AbbVie Company, São Paulo, Brazil.
Plast Reconstr Surg Glob Open. 2024 Sep 19;12(9):e6190. doi: 10.1097/GOX.0000000000006190. eCollection 2024 Sep.
HA/CaHa (HArmonyCa, Allergan Aesthetics, an AbbVie Company) is a hybrid injectable filler developed for aesthetic purposes that contains calcium hydroxyapatite microspheres suspended in a hyaluronic acid gel. This review describes preclinical and clinical data, recommendations for use based on the primary author's clinical experience, and case studies that illustrate implementation of product use recommendations and patient outcomes.
Preclinical data on the lift capacity and tissue integration of the HA/CaHa hybrid injectable and clinical data on its safety, efficacy, and real-world use were extracted from poster presentations, published literature, manufacturer instructions for use, and proprietary data files. Case studies were presented based on clinical experience.
The HA component of HA/CaHa provides an immediate and noticeable filling and lifting effect, whereas CaHa microspheres result in neocollagenesis. In preclinical studies, HA/CaHa demonstrated higher lift capacity ( < 0.05) and faster tissue integration than a CaHa filler and led to collagen I gene and protein expression. Clinical studies showed clinical safety and effectiveness with high patient satisfaction. The most common adverse event was injection-site response. Clinician recommendations for achieving desired aesthetic results while minimizing or preventing adverse events are reviewed, including patient selection and assessment, treatment approaches based on face shape, injection technique, and postprocedure care.
The novel hybrid injectable consisting of HA with incorporated CaHa microspheres in a single marketed product may help achieve aesthetic goals by immediately restoring volume and potentially improving skin architecture and soft-tissue quality over time.
HA/CaHa（HarmonyCa，艾尔建美学公司，艾伯维旗下公司）是一种用于美容目的的混合注射填充剂，其含有悬浮于透明质酸凝胶中的羟基磷灰石微球。本综述描述了临床前和临床数据、基于第一作者临床经验的使用建议，以及说明产品使用建议实施情况和患者治疗效果的案例研究。
从海报展示、已发表文献、制造商使用说明和专有数据文件中提取关于HA/CaHa混合注射填充剂提升能力和组织整合的临床前数据，以及关于其安全性、有效性和实际应用的临床数据。基于临床经验呈现案例研究。
HA/CaHa中的透明质酸（HA）成分可提供即时且显著的填充和提升效果，而羟基磷灰石（CaHa）微球则可促进新胶原生成。在临床前研究中，HA/CaHa相较于一种CaHa填充剂显示出更高的提升能力（P<0.05）和更快的组织整合，并导致I型胶原基因和蛋白表达。临床研究表明其具有临床安全性和有效性，患者满意度高。最常见的不良事件为注射部位反应。本文综述了临床医生为实现理想美容效果同时最小化或预防不良事件所提出的建议，包括患者选择与评估、基于面部形状的治疗方法、注射技术及术后护理。
在单一市售产品中由HA与CaHa微球组成的新型混合注射填充剂，可能通过即时恢复容积并随着时间推移潜在改善皮肤结构和软组织质量，有助于实现美容目标。
